JA Baron, BF Cole, RS Sandler, RW Haile, D … - The New England journal of medicine, 2003 - nejm.highwire.org Methods We performed a randomized, double-blind trial of aspirin as a
chemopreventive agent against colorectal adenomas. We randomly assigned 1121
patients with a recent history of histologically documented adenomas to ... Cited by 721 - Related articles - BL Direct - All 8 versions
- ►pubget.com [PDF] RS Sandler, S Halabi, JA Baron, S Budinger, E … - New England Journal of Medicine, 2003 - content.nejm.org Methods We conducted a randomized, double-blind trial to determine the effect of
aspirin on the incidence of colorectal adenomas. We randomly assigned 635
patients with previous colorectal cancer to receive either 325 mg of ... Cited by 568 - Related articles - BL Direct - All 19 versions
- ►aacrjournals.org M Yao, S Kargman, EC Lam, CR Kelly, Y … - Cancer research, 2003 - AACR A large number of epidemiological studies have shown that regular use of
aspirinor other nonsteroidal anti-inflammatory drugs (NSAIDs) results in a
40–50% reduced risk of colorectal cancer (CRC). Furthermore, NSAIDs cause ... Cited by 176 - Related articles - BL Direct - All 8 versions
- ►annals.org [PDF] AT Chan, EL Giovannucci, ES Schernhammer, … - Annals of internal medicine, 2004 - Am Coll Physicians Background: Randomized, double-blind, placebo-controlled tri- als have
established that regular aspirin use reduces the risk for recurrent colorectal
adenoma. However, the effect of dose and duration of use, particularly in ... Cited by 88 - Related articles - BL Direct - All 8 versions
JA Baron - Cox-2: A New Target for Cancer Prevention and …, 2003 - books.google.com Dannenberg AJ, DuBois RN (eds): COX-2. Prog Exp Tum Res. Basel, Karger, 2003,
vol 37, pp 1-24 Epidemiology of Non-Steroidal Anti-Inflammatory Drugs and Cancer
John A. Baron Departments of Medicine, and Community and Family Medicine, ... Cited by 86 - Related articles - BL Direct - All 7 versions
K Song, AM Fendrick, U Ladabaum - Gastroenterology, 2004 - Elsevier : Fecal DNA testing is an emerging tool to detect colorectal cancer (CRC). Our
aims were to estimate the clinical and economic consequences of fecal DNA
testing vs. conventional CRC screening. : Using a Markov model, we ... Cited by 83 - Related articles - BL Direct - All 12 versions
U Ladabaum, K Song, AM Fendrick - Clinical Gastroenterology and Hepatology, 2004 - Elsevier When optimized, virtual colonoscopy may be highly sensitive for colorectal
neoplasia. We evaluated the effectiveness and cost-effectiveness of virtual
colonoscopy screening (VC) vs. colonoscopy screening (COLO) and the ... Cited by 68 - Related articles - BL Direct - All 17 versions
- ►annals.org [PDF] M Pignone, S Earnshaw, JA Tice, MJ Pletcher - Annals of internal medicine, 2006 - Am Coll Physicians Page 1. Aspirin, Statins, or Both Drugs for the Primary Prevention of Coronary
Heart Disease Events in Men: A Cost–Utility Analysis ... Cited by 64 - Related articles - BL Direct - All 6 versions
U Ladabaum, K Song - Gastroenterology, 2005 - Elsevier Background & Aims: Colorectal cancer (CRC) screening is effective and
cost-effective, but the potential national impact of widespread screening is
uncertain. It is controversial whether screening colonoscopy can be offered ... Cited by 63 - Related articles - All 14 versions
PJ Pickhardt, C Hassan, A Laghi, A Zullo, DH … - Cancer, 2007 - colonhealthcenters.com BACKGROUND. Prior cost-effectiveness models analyzing computed tomography
colonography (CTC) screening have assumed that patients with diminutive lesions
( 5 mm) will be referred to optical colonoscopy (OC) for polypectomy. ... Cited by 63 - Related articles - View as HTML - BL Direct - All 6 versions
